Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFR Benefits from Furmonertinib after Acquiring Gefitinib Resistance: A Case Report

CONCLUSION: Pulmonary adenocarcinoma with rare rare complex mutations in EGFR induced by gefitinib resistance and disease progression might benefit from furmonertinib treatment.PMID:38214361 | DOI:10.2174/1574892818666230316145232
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Authors: Source Type: research